AC
REGN icon

Avestar Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Avestar Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
673
+14
+2% +$9.53K 0.02% 409
2026
Q1 		$509K Buy
659
+24
+4% +$18.4K 0.03% 349
2025
Q4 		$490K Sell
635
-295
-32% -$200K 0.03% 342
2025
Q3 		$523K Buy
930
+420
+82% +$237K 0.03% 332
2025
Q2 		$268K Sell
510
-164
-24% -$91.5K 0.02% 410
2025
Q1 		$427K Sell
674
-113
-14% -$77.7K 0.04% 315
2024
Q4 		$561K Buy
787
+64
+9% +$53.7K 0.05% 264
2024
Q3 		$760K Buy
723
+52
+8% +$57.9K 0.08% 196
2024
Q2 		$705K Sell
671
-17
-2% -$16.5K 0.07% 197
2024
Q1 		$662K Buy
688
+323
+88% +$307K 0.07% 201
2023
Q4 		$321K Buy
+365
New +$301K 0.04% 282
2019
Q3 		– Sell
-78
Closed -$21K – 685
2019
Q2 		$21K Sell
78
-7
-8% -$2.33K 0.01% 388
2019
Q1 		$33K Sell
85
-209
-71% -$86.1K 0.02% 329
2018
Q4 		$87K Sell
294
-54
-16% -$19.8K 0.06% 197
2018
Q3 		$122K Buy
348
+57
+20% +$21.7K 0.07% 175
2018
Q2 		$85K Buy
291
+26
+10% +$8.13K 0.05% 217
2018
Q1 		$77K Buy
265
+92
+53% +$32K 0.05% 204
2017
Q4 		$45K Buy
+173
New +$70.1K 0.03% 261

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Avestar Capital's REGN Position: Q2 2026 in Review

Avestar Capital increased its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q2 2026, buying an estimated $9.53K and bringing the position to 673 shares worth $420K. The position accounts for 0.02% of the portfolio, ranked #409.

Avestar Capital first reported a position in REGN in Q4 2017 and has held it in 18 quarters since. The position peaked at $760K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Avestar Capital held 673 shares of Regeneron Pharmaceuticals worth $420K as of Q2 2026.
  • Avestar Capital bought 14 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $9.53K.
  • Regeneron Pharmaceuticals made up 0.02% of Avestar Capital's portfolio in Q2 2026, its #409 holding.
  • Avestar Capital first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
  • Avestar Capital's Regeneron Pharmaceuticals position peaked at $760K in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.